



UCB's shareholder meeting today

- For financial year 2015:
Gross dividend of € 1.10 per share (+ 4%), payable 3 May 2016
- Financial outlook for 2016 confirmed
- All agenda items put to vote approved

Brussels (Belgium), 28 April 2016 – 18:00 (CEST) – regulated information

Today, UCB held its Annual General Meeting (AGM) and Extraordinary General Meeting (EGM). At the AGM, 152 429 300 million shares (81.06 % of shares entitled to vote) were represented. During the course of this meeting, Jean-Christophe Tellier, Chief Executive Officer UCB, gave the shareholders of UCB an overview of UCB's patient value and growth strategy priorities, the financial year 2015 and the first three months of 2016. He also confirmed the financial outlook for 2016.

The AGM approved for the fiscal year 2015 the payment of a gross dividend of € 1.10 per share (net dividend of € 0.803 per share) compared to € 1.06 per share for 2014 (net € 0.795). The ex-dividend day is 29 April 2016, the dividend (coupon no. 19) will be payable on 3 May 2016.

The AGM re-appointed Harriet Edelman as independent director and Charles-Antoine Janssen as director, and appointed Ulf Wiinberg and Pierre Gurdjian as independent directors. For the curriculum vitae of the Board members, please visit the UCB website:

<http://www.ucb.com/investors/Governance/Corporate-governance>.

All other agenda items put to vote of the Annual General Meeting as well as all agenda items of the Extraordinary General Meeting were approved by the shareholders present and represented. More information including details of the votes will be available soon on UCB's website:

<http://www.ucb.com/investors/Governance/Shareholders-meeting>.

The Annual Report 2015 of UCB is available on UCB's website:

<http://www.ucb.com/investors/Financials/Annual-reports>.

The financial results for the first half year 2016 will be published on 28 July 2016 and an interim report for the first nine months of 2016 is due on 25 October 2016.

Next year's AGM will be held on 27 April 2017 in Brussels (Belgium).

For further information

Investor Relations

Antje Witte, Investor Relations, UCB
T +32 2 559 94 14, antje.witte@ucb.com

Isabelle Ghellynck, Investor Relations, UCB
T +32.2.559.9588, isabelle.ghellynck@ucb.com

Corporate Communications

France Nivelles, Global Communications, UCB
T +32.2.559.9178, france.nivelles@ucb.com

Laurent Schots, Media Relations, UCB
T +32.2.559.9264, laurent.schots@ucb.com

About UCB



UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 700 people in approximately 40 countries, the company generated revenue of € 3.9 billion in 2015. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

Forward looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this presentation and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.